Tetraphase Pharmaceuticals Inc. (TTPH)

3.04
NASDAQ : Health Technology
Prev Close 3.09
Day Low/High 3.03 / 3.15
52 Wk Low/High 2.05 / 8.75
Avg Volume 640.70K
Exchange NASDAQ
Shares Outstanding 51.63M
Market Cap 159.54M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Investigation Of Tetraphase Pharmaceuticals Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Tetraphase Pharmaceuticals Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Tetraphase Pharmaceuticals, Inc.

First Week of August 17th Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week of August 17th Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the August 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Interesting TTPH Call Options For January 2018

Interesting TTPH Call Options For January 2018

Investors in Tetraphase Pharmaceuticals, Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TTPH options chain for the new January 2018 contracts and identified the following call contract of particular interest.

RSI Alert: Tetraphase Pharmaceuticals (TTPH) Now Oversold

RSI Alert: Tetraphase Pharmaceuticals (TTPH) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Tetraphase Pharmaceuticals Presents Clinical Data From Oral Eravacycline Development Program At IDWeek 2017

Tetraphase Pharmaceuticals Presents Clinical Data From Oral Eravacycline Development Program At IDWeek 2017

- Company plans to advance current oral eravacycline formulation into a phase 2 study in 1H18 -

First Week of May 2018 Options Trading For Tetraphase Pharmaceuticals (TTPH)

First Week of May 2018 Options Trading For Tetraphase Pharmaceuticals (TTPH)

Investors in Tetraphase Pharmaceuticals, Inc saw new options become available this week, for the May 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Tetraphase Pharmaceuticals Stock Sees Short Interest Increase 32.8%

Tetraphase Pharmaceuticals Stock Sees Short Interest Increase 32.8%

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 961,370 share increase in total short interest for Tetraphase Pharmaceuticals, Inc , to 3,889,264, an increase of 32.83% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D (Sell)